Quant Healthcare Fund
The scheme seeks to long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
Growthvine rating: 3/5 — ranked #23 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹16.60 (as of 2026-10-23) |
|---|
| AUM | ₹425 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ayusha Kumbhat |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| Sharpe ratio | 0.72 |
|---|
| Standard deviation | 18.33% |
|---|
| Max drawdown | −25.79% |
|---|
| Alpha | -1.8 |
|---|
| Beta | 0.97 |
|---|
Over 5 years, captured 88.0% of NIFTY Pharma's upside and 76.0% of its downside.
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 54.3% |
|---|
| Small cap | 45.7% |
|---|
Concentration
| Top 5 holdings | 47.1% |
|---|
| Top 10 holdings | 80.4% |
|---|
| Total holdings | 17 |
|---|
Top holdings
- TREPS 01-Oct-2026 DEPO 10 — 26.6%
- GlaxoSmithkline Pharmaceuticals Ltd. — 9.7%
- Divis Laboratories Ltd. — 9.6%
- Zydus Lifesciences Limited — 9.4%
- Glenmark Pharmaceuticals Ltd. — 9.3%
- STRIDES PHARMA SCIENCE LIMITED — 9.0%
- Torrent Pharmaceuticals Ltd. — 8.6%
- Pfizer Ltd. — 7.4%
- ALIVUS LIFE SCIENCES LIMITED — 6.2%
- Ipca Laboratories Ltd. — 6.0%
Top sectors
- Pharma & Biotech — 58.1%
- Derivatives — 32.1%
- SOV — 6.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 10.9% | Q1 (Top) | #8 of 76 |
| 2025 | −5.2% | Q4 (Bottom) | #57 of 69 |
| 2024 | 29.7% | Q2 | #23 of 58 |